MRNA Moderna
- 140.030
- -5.200-3.58%
- 140.000
- -0.030-0.02%
Moderna News
Moderna Just Gave Investors Another Reason to Buy the Stock
Worried You Missed the Nvidia Bandwagon? Here -2-
AMD is an example of a large company on the list that is expected to grow sales at a rapid clip through 2026, with a P/E that is lower than Nvidia's. AMD's P/E is also a bit lower than it was a year a
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Moderna(MRNA.US) Director Sells US$2.21 Million in Common Stock
$Moderna(MRNA.US)$ Director AFEYAN NOUBAR sold 15,000 shares of common stock on Jun 12, 2024 at an average price of $147.2048 for a total value of $2.21 million.Source: Announcement What is statement
Moderna Stock Traded in the Red for Seven Straight Days
Express News | FDA Says On June 13 Updates Advice To Manufacturers Of Covid-19 Vaccines (2024-2025 Formula): If Feasible Use KP.2 Strain Of JN.1-Lineage
CDC 'Preparing for the Possibility' Bird Flu Could Spread More Easily
Moderna (NASDAQ:MRNA) Shareholders Are Still up 857% Over 5 Years Despite Pulling Back 6.1% in the Past Week
TD Cowen Maintains Moderna(MRNA.US) With Hold Rating, Maintains Target Price $75
TD Cowen analyst Tyler Van Buren maintains $Moderna(MRNA.US)$ with a hold rating, and maintains the target price at $75.According to TipRanks data, the analyst has a success rate of 42.3% and a total
Moderna's Covid-19 Vaccine Meets Primary Efficacy Endpoint in Phase III Trial
News Highlights: Top Company News of the Day - Thursday at 7 PM ET
Tesla Shareholders Vote to Uphold Musk's Pay Plan The move signals support for the EV maker's longtime leader and gives the board ammunition in its fight to preserve the court-rejected compensation p
FDA Recommends KP.2 Strain Be Used in Updated COVID-19 Shots
Moderna Says New-generation COVID Vaccine More Effective Than Spikevax for Adults 18 and Over
A consistent trend was seen in a subset of adults aged 65 and older
Moderna Says New-generation COVID Vaccine More Effective Than Spikevax
Moderna Inc. (MRNA) said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher efficacy in adults compared to its original vaccine dubbed Spikevax. The r
Moderna Reaffirms Phase 3 Win for Next-gen COVID Shot
Express News | Moderna Says MRNA-1283 Met Its Primary Vaccine Efficacy Endpoint In Phase 3 Trial
Express News | Moderna - in Trial, Mrna-1283 Was Found to Have a Similar Safety Profile to Spikevax
Express News | Moderna - Mrna-1283 Has Now Met Its Primary Vaccine Efficacy Endpoint in Phase 3
Express News | Moderna - Phase 3 Trial of Mrna-1283, an Investigational Next-Generation Covid-19 Vaccine, Has Met Its Primary Efficacy Endpoint
Express News | Moderna: Higher Efficacy Was Observed in Mrna-1283 Compared to Spikevax in Adults 18 Years of Age and Older
Analysis
Price Target
No Data
